Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned a consensus rating of “Hold” from the fourteen analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $129.22.
A number of brokerages have commented on UTHR. Credit Suisse Group raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $98.00 price target on the stock in a research report on Thursday, May 9th. Wedbush set a $273.00 price target on shares of United Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 8th. BidaskClub cut shares of United Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. ValuEngine cut shares of United Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, April 18th. Finally, Barclays dropped their price objective on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating on the stock in a report on Friday, March 1st.
UTHR traded up $1.63 during trading on Tuesday, reaching $85.37. 7,709 shares of the stock traded hands, compared to its average volume of 866,297. The company has a current ratio of 7.19, a quick ratio of 6.84 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $3.68 billion, a P/E ratio of 6.38 and a beta of 1.15. United Therapeutics has a 12 month low of $82.78 and a 12 month high of $130.00.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) EPS for the quarter, missing the Zacks’ consensus estimate of $2.64 by ($13.96). The firm had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The business’s revenue was down 6.8% compared to the same quarter last year. During the same period last year, the company posted $3.76 EPS. As a group, research analysts predict that United Therapeutics will post -5.03 EPS for the current fiscal year.
In other news, Director Christopher Patusky sold 3,370 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 8.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Vanguard Group Inc raised its position in United Therapeutics by 1.7% during the third quarter. Vanguard Group Inc now owns 3,775,103 shares of the biotechnology company’s stock valued at $482,760,000 after buying an additional 61,361 shares during the period. Arizona State Retirement System raised its position in United Therapeutics by 1.1% during the fourth quarter. Arizona State Retirement System now owns 31,284 shares of the biotechnology company’s stock valued at $3,407,000 after buying an additional 352 shares during the period. Wedge Capital Management L L P NC raised its position in United Therapeutics by 9.3% during the fourth quarter. Wedge Capital Management L L P NC now owns 295,418 shares of the biotechnology company’s stock valued at $32,171,000 after buying an additional 25,075 shares during the period. Rhumbline Advisers raised its position in United Therapeutics by 37.7% during the fourth quarter. Rhumbline Advisers now owns 109,108 shares of the biotechnology company’s stock valued at $11,882,000 after buying an additional 29,895 shares during the period. Finally, First Mercantile Trust Co. raised its position in United Therapeutics by 47.8% during the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 96.46% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: Recession
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.